FGF2 and prostate cancer: In the dominant effect models (referent: wild-type homozygote) there were significant decreases in risk for LEPR Gln223Arg (aOR = 0.6, 95%CI: 0.5–0.8, aOR = 0.6, 95%CI: 0.5–0.8 and aOR = 0.5, 95%CI: 0.4–0.8, for all, high-grade and high-risk prostate cancer for metastasis, respectively) and for FGF2+223 C>T (aOR = 0.7, 95%CI: 0.5–1.0 in high-grade prostate cancer).